文献速递白血病

CD371阳性儿童B细胞急性淋巴细胞白血病:易发生谱系转换且早期治疗反应缓慢

CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment.
PubMed 文献 · Blood · 2024-01-01

在AIEOP-BFM ALL 2009试验纳入的1812例新诊断儿童B细胞前体急性淋巴细胞白血病中,160例(8.8%)为CD371阳性,与较大年龄、较低ETV6::RUNX1频率、免疫表型不成熟及CD34和CD45强表达相关,诱导治疗期间出现短暂髓单核细胞转换且早期化疗反应较差,但5年无事件生存率为88.3%。

要点

  • CD371阳性见于8.8%(160/1812)儿童B细胞前体急性淋巴细胞白血病。
  • CD371阳性者诱导第15天髓单核细胞转换率高达65.4%,早期化疗反应差(P<.001)。
  • 尽管早期反应差,5年无事件生存率仍达88.3%。

核心结论

  • CD371是短暂髓单核细胞转换最敏感的标记,识别该转换对正确进行流式细胞术微小残留病评估至关重要。
  • CD371阳性与早期治疗反应差相关,但经基于微小残留病的急性淋巴细胞白血病相关治疗后仍可获得良好结局。

研究设计与样本

  • 国际柏林-法兰克福-明斯特流式网络开展的前瞻性特征分析,纳入AIEOP-BFM ALL 2009试验中2014年6月至2017年2月新诊断的1812例儿童B细胞前体急性淋巴细胞白血病患者。
  • 患者分为筛查队列(n=843,意大利中心)和验证队列(n=969,其他国际柏林-法兰克福-明斯特中心)。
  • 诊断时进行形态学、免疫表型和遗传学分析;反应评估采用形态学、多参数流式细胞术和聚合酶链反应微小残留病检测。

主要发现

  • 诊断时160/1812(8.8%)B细胞前体急性淋巴细胞白血病为CD371阳性。
  • CD371阳性与较大年龄、较低ETV6::RUNX1频率、免疫表型不成熟(均P<.001)及CD34和CD45强表达(P<.05)相关。
  • 诱导治疗期间CD371阳性者出现短暂髓单核细胞转换,第15天样本中高达65.4%,且化疗反应较差(早期反应缓慢,P<.001)。
  • 5年无事件生存率为88.3%。
  • 验证队列420例患者中,28例DUX4融合阳性者中27例(96.4%)为CD371阳性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the effort to improve immunophenotyping and minimal residual disease (MRD) assessment in acute lymphoblastic leukemia (ALL), the international Berlin-Frankfurt-Münster (iBFM) Flow Network introduced the myelomonocytic marker CD371 for a large prospective characterization with a long follow-up. In the present study, we aimed to investigate the clinical and biological features of CD371-positive (CD371pos) pediatric B-cell precursor ALL (BCP-ALL). From June 2014 to February 2017, 1812 pediatric patients with newly diagnosed BCP-ALLs enrolled in trial AIEOP-BFM ALL 2009 were evaluated as part of either a screening (n = 843, Italian centers) or validation cohort (n = 969, other iBFM centers). Laboratory assessment at diagnosis consisted of morphological, immunophenotypic, and genetic analysis. Response assessment relied on morphology, multiparametric flow cytometry (MFC), and polymerase chain reaction (PCR)-MRD. At diagnosis, 160 of 1812 (8.8%) BCP-ALLs were CD371pos. This correlated with older age, lower ETV6::RUNX1 frequency, immunophenotypic immaturity (all P < .001), and strong expression of CD34 and of CD45 (P < .05). During induction therapy, CD371pos BCP-ALLs showed a transient myelomonocytic switch (mm-SW: up to 65.4% of samples at day 15) and an inferior response to chemotherapy (slow early response, P < .001). However, the 5-year event-free survival was 88.3%. Among 420 patients from the validation cohort, 27 of 28 (96.4%) cases positive for DUX4-fusions were CD371pos. In conclusion, in the largest pediatric cohort, CD371 is the most sensitive marker of transient mm-SW, whose recognition is essential for proper MFC MRD assessment. CD371pos is associated to poor early treatment response, although a good outcome can be reached after MRD-based ALL-related therapies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Buldini B, Varotto E, Maurer-Granofszky M, et al. CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment. Blood. 2024. PMID: 38215390. doi:10.1182/blood.2023021952

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。